•  

     

     

     

     

     

     

    World AMR Congress

    INNOVATE.
    COLLABORATE.
    COMMERCIALIZE.

    Bringing together pharma, biotech, hospitals, Government and their partners to discuss the world's most important health issue.

    SPONSORSHIP IS NOW SOLD OUT!

    Only 4  Delegate Passes Left: Register now to secure yours!

     

     

     

     

  • Visionary keynotes

    Inspiring case studies

    Interactive roundtable discussions

  • Only 4 delegate passes remaining! Make sure one of them is yours

FACING A GLOBAL HEALTH CRISIS

 

The World AntiMicrobial Resistance Congress USA gathers C-level decision makers from government, funding agencies, pharma, academia, hospitals, labs, and payers to discuss the urgent need for new antibiotics. The Review on Antimicrobial Resistance released their final report this year outlining the rising danger of AMR and the steps that must be taken in order to overcome this danger. This event is about gathering the experts in the industry to determine how best to approach taking these necessary steps. 

This 2-day conference presents solutions through key notes, case study presentations, expert opinion and roundtable discussions, and invites key influencers such as BARDA, NIH, FDA, grant agencies, pharma and academia, in the AMR discussion. This is the 2-day exhibition and conference you cannot afford to miss.

 

" The evolution of antibiotic resistance is now occurring at an alarming rate and is outpacing the development of new countermeasures capable of thwarting infections in humans. "

President Barack Obama

Meet the experts

 

The World Anti-Microbial Resistance Congress 2016 is bringing togehter all of the greatest minds in the antimicrobial field together to tackle this very issue. It’s time to stop talking about the problem and start discussing solutions, which is why we brought in Pharma, academia and the government.

 

  • Rosemarie Aurigemma at World Anti-Microbial Congress US 2016
    Rosemarie Aurigemma
    Chief Biodefense Drug Development Section
    NIAID, NIH
    Mr Stefano Bertuzzi at World Anti-Microbial Congress US 2016
    Mr Stefano Bertuzzi
    Executive Director/CEO
    American Society for Microbiology
  • James Del Rosso at World Anti-Microbial Congress US 2016
    James Del Rosso
    DO, FAOCD, FAAD, Adjunct Clinical Professor, (Dermatology)
    Touro University Nevada
    Michael Draper at World Anti-Microbial Congress US 2016
    Michael Draper
    Senior Director, External Science and Partnering
    Sanofi
  • Michael Dudley at World Anti-Microbial Congress US 2016
    Michael Dudley
    Senior Vice President of Research and Development and Chief Scientific Officer
    The Medicines Company
    Barry Eisenstein at World Anti-Microbial Congress US 2016
    Barry Eisenstein
    Distinguished Physician, Antimicrobials
    Merck & Co.
  • Robert Eisinger at World Anti-Microbial Congress US 2016
    Robert Eisinger
    Senior Health Science Policy Advisor, Division of Program Coordination, Planning, and Strategic Initiatives,
    NIH
    Fabrizio Ensoli at World Anti-Microbial Congress US 2016
    Fabrizio Ensoli
    Head,Pathology and Microbiology
    Sapienza University of Rome
  • Marcos Espinal at World Anti-Microbial Congress US 2016
    Marcos Espinal
    Director, Department of Communicable Diseases and Health Analysis
    PAHO/WHO
    Scott Evans at World Anti-Microbial Congress US 2016
    Scott Evans
    Director of the Statistical and Data Management Center (SDMC) for the Antibacterial Resistance Leadership Group (ARLG)
    Harvard University
  • Tamar Ghosh at World Anti-Microbial Congress US 2016
    Tamar Ghosh
    Lead, Longitude Prize
    Nesta
    Steven Gilman at World Anti-Microbial Congress US 2016
    Steven Gilman
    Chairman & CEO
    Contrafect Corporation
  • Judy Hackett at World Anti-Microbial Congress US 2016
    Judy Hackett
    Project Coordinator, Drive-AB, Global Payer Evidence Director
    AstraZeneca
    Chris Houchens at World Anti-Microbial Congress US 2016
    Chris Houchens
    PhD, Branch Chief (Acting), Antibacterials Program
    BARDA
  • Hasan Jafri at World Anti-Microbial Congress US 2016
    Hasan Jafri
    Senior Director, Clinical Research and Development Infectious Diseases and Vaccines MedImmune, AstraZeneca,Coordinator, COMBACTE
    Innovative Medicines Initiative
    François Jehl at World Anti-Microbial Congress US 2016
    François Jehl
    Bacteriology Lab manager, Hospital Strasbourg, France, Coordinator, Antimicrobial Committee
    French Society for Microbiology
  • Anders Karlén at World Anti-Microbial Congress US 2016
    Anders Karlén
    Managing Entity, ENABLE, Professor in Computer-aided Drug Design
    Uppsala University
    Barbara Kerstiens at World Anti-Microbial Congress US 2016
    Barbara Kerstiens
    Deputy Head of Unit, Fighting Infectious Diseases and Advancing Public Health Research and Innovation Directorate-General
    European Commission
  • Dr Jane Knisely at World Anti-Microbial Congress US 2016
    Dr Jane Knisely
    Program Officer, Bacteriology and Mycology Branch, NIAID
    NIH - NIAID
    Joe Larsen at World Anti-Microbial Congress US 2016
    Joe Larsen
    Acting Deputy Director
    BARDA
  • Frédéric Laurent at World Anti-Microbial Congress US 2016
    Frédéric Laurent
    Professor of Microbiology, National Reference Center on Staphylococcus
    University Hospital, Lyon
    Ankit Mahadevia at World Anti-Microbial Congress US 2016
    Ankit Mahadevia
    Chief Executive Officer
    Spero Therapeutics
  • David Mantus at World Anti-Microbial Congress US 2016
    David Mantus
    Chief Development Officer
    Arsanis Inc
    Anthony McDonnell at World Anti-Microbial Congress US 2016
    Anthony McDonnell
    Head of Economic Research
    Review on Antimicrobial Resistance
  • Sumathi Nambiar at World Anti-Microbial Congress US 2016
    Sumathi Nambiar
    Director, Division of Aniti-Infective Products
    FDA
    Professor Kevin Outterson at World Anti-Microbial Congress US 2016
    Professor Kevin Outterson
    Professor of Health Law, Bioethics and Human Rights
    Boston University School of Law
  • Jean Patel at World Anti-Microbial Congress US 2016
    Jean Patel
    Deputy Director, Office of Antimicrobial Resistance
    Center for Disease Control & Prevention
    Robin Patel at World Anti-Microbial Congress US 2016
    Robin Patel
    Professor of Microbiology and Medicine
    Mayo Clinic
  • Edmund Pezalla at World Anti-Microbial Congress US 2016
    Edmund Pezalla
    VP
    Aetna Pharmacy Management
    Aleks Radovic-Moreno at World Anti-Microbial Congress US 2016
    Aleks Radovic-Moreno
    Senior Associate
    PureTech Health
  • Ribhi Shawar at World Anti-Microbial Congress US 2016
    Ribhi Shawar
    Branch Chief, Division of Microbiology
    CDRH OIR FDA
    Carolyn Shore at World Anti-Microbial Congress US 2016
    Carolyn Shore
    Officer of Antibiotic Resistance Project
    The Pew Charitable Trusts
  • Mr Larry Tsai at World Anti-Microbial Congress US 2016
    Mr Larry Tsai
    VP, Clinical Development
    Tetraphase Pharmaceuticals
    Mr Lucas Wiarda at World Anti-Microbial Congress US 2016
    Mr Lucas Wiarda
    Global Marketing Director & Head of Sustainable Antibiotics Program
    DSM Sinochem Pharmaceuticals
  • David Huang at World Anti-Microbial Congress US 2016
    David Huang
    Chief Medical Officer
    Motif Bio
    Dawn O'Connell at World Anti-Microbial Congress US 2016
    Dawn O'Connell
    Deputy Chief of Staff
    United States Department of Health & Human Services
  • Jennifer Auchtung at World Anti-Microbial Congress US 2016
    Jennifer Auchtung
    Assistant Professor, Therapeutic Microbiology Laboratory, Dept. of Molecular Virology and Microbiology
    Baylor College of Medicine
    Byron Beeler at World Anti-Microbial Congress US 2016
    Byron Beeler
    Board Member
    Natural MA
  • Dr Debabrata Biswas at World Anti-Microbial Congress US 2016
    Dr Debabrata Biswas
    Assistant Professor
    University of Maryland University College
    Ramiz Boulos at World Anti-Microbial Congress US 2016
    Ramiz Boulos
    CEO
    Boulos & Cooper
  • Dr Nick Conley at World Anti-Microbial Congress US 2016
    Dr Nick Conley
    Chief Executive Officer
    EpiBiome
    Mr David Larwood at World Anti-Microbial Congress US 2016
    Mr David Larwood
    CEO and Founder
    Valley Fever Solutions
  • James Liang at World Anti-Microbial Congress US 2016
    James Liang
    Professor, Department of Biomedical Engineering, Chemistry and Biology
    Stevens Institute of Technology
    Randy D Milby at World Anti-Microbial Congress US 2016
    Randy D Milby
    Chief Executive Officer
    CorMedix Inc.
  • Mr Neil Miller at World Anti-Microbial Congress US 2016
    Mr Neil Miller
    Chief Scientific Officer
    Auspherix Ltd
    Mr Steve Parkinson at World Anti-Microbial Congress US 2016
    Mr Steve Parkinson
    President and Chief Executive Officer
    Lakewood-Amedex Inc.
  • Mr Malcolm Thomas at World Anti-Microbial Congress US 2016
    Mr Malcolm Thomas
    COO
    Agile Sciences, Inc.
    Barry Wohl at World Anti-Microbial Congress US 2016
    Barry Wohl
    CBO
    SymbalRx
  • Robert Yancey, Jr. at World Anti-Microbial Congress US 2016
    Robert Yancey, Jr.
    Infectious Diseases Consultant
    Antibiotic Adjuvant, Inc

 

 

Introducing the new and improved Pitch & Partner
 

 

Present your research to potential investors

This is the opportunity to pitch your new antibiotic or treatment alternative to those who are looking for the next promising developments in fighting AMR.

Antibiotic Development and Stewardship Included

Presentations will be made in the areas of both antibiotic development and stewardship, highlighting the latest advances in both new antibiotics and alternative therapies for drug-resistant infections. 

 

Make the connection

This is the chance to meet the right people who can set your research on the path to development and success. Take the opportunity to display what you've been working on to those who can truly be instrumental in setting development for your antibiotic or therapy in motion.

 

 

 

" [AMR] is an increasingly serious threat to global public health that requires action across all government sectors and society. "

World Health Organization

WHO ATTENDS?

Here's a glimpse of who attended in 2015

 

Achaogen Actavis Alliance for Aging Research Arsanis Inc. AstraZeneca BARDA   Basilea Pharmaceutica Biofilm Control Bio-Manguinhos/Fiocruz Biomerieux Inc.   Catholic University of Brasilia CDC College of Staten Island Crestone Inc. DSM Sinochem Pharmaceuticals Emergent BioSolutions Entasis Therapeutics Evotec  George Washington University IMMT InnoTune BVBA Innovative Medicines Initiative Institute for Life Science Entrepreneurship, Kean University Janssen Pharmaceuticals, Ltd. Massachusetts General Hospital McMaster University Merck Motif Biosciences, Inc. MRI Global NIH-NIAID Northeastern University Novan Therapeutics Ohio Northern University Pennsylvania State University   Public Health England Raleigh Fitkin Memorial Hospital Roche Innovation Center New York Sanofi Shionogi Inc. Spero Therapeutics SUNY Buffalo Telephus Medical LLC The Medicines Company The Pew Charitable Trusts Tiber Creek Partners UCLA David Geffen School of Medicine UMSL United States Department of Health and Human Services University of California Merced University of Rochester Medical Center University of Warwick Vanderbilt University VenatoRx Pharmaceuticals Inc. The Wellcome Trust  Zeus Capital   

 

FIND OUT MORE

 

Our Sponsors & Exhibitors

 

  • Platinum Sponsor

    Biofilm Control at World Anti-Microbial Congress US 2016
  • Gold Sponsor

    PSI CRO at World Anti-Microbial Congress US 2016
  • Gold Sponsor

    Cepheid at World Anti-Microbial Congress US 2016
  • Silver Sponsor

    bioMérieux at World Anti-Microbial Congress US 2016
  • Silver Sponsor

    OpGen Inc at World Anti-Microbial Congress US 2016
  • Associate Sponsor

    BD Diagnostics at World Anti-Microbial Congress US 2016
  • Exhibitor

    Diversigen Inc at World Anti-Microbial Congress US 2016
 

JOIN THE 2017 WAITING LIST

" We’re in the post-antibiotic era. There are patients for whom we have no therapy, and we are literally in a position of having a patient in a bed who has an infection, something that five years ago even we could have treated, but now we can’t. "

Dr. Arjun Srinivasan, Centers for Disease Control and Prevention (CDC)

Register Now

THIS CONFERENCE WILL SELL OUT!
Early registration and partner discounts available.
Click below for the full list of ticket options...

 

REGISTER NOW

 

Error processing SSI file